Shop

Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Press Releases

7 May 2024

Numinus Wellness Focused on Boosting Profitability and Expanding Community Support

As part of the strategic plan, Numinus has entered into an agreement with the Canadian Centre for Psychedelic Healing ("Field Trip Health"), which provides psychedelic-assisted therapy in five Canadian clinics...

By Madison Roberts

Science

6 May 2024

Innovating CNS Disorder Treatment: EQUULUS and the Revolutionary Approach with Analog Ibogaine

Navigating the complex landscape of pharmaceutical development for central nervous system (CNS) disorders is no small feat. Current treatments vary widely, from antipsychotics to antidepressants and mood stabilizers. However, for...

By Madison Roberts

Press Releases

6 May 2024

Lykos Therapeutics Announces FDA Advisory Committee Meeting to Review Investigational MDMA-Assisted Therapy for PTSD

The U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory Committee ("PDAC") will review data supporting the new drug application ("NDA") for midomafetamine (MDMA) capsules used in combination with psychological...

By Madison Roberts

Science

3 May 2024

Ketamine-Assisted Psychotherapy for Chronic Pain and Depression

Chronic pain and depression are major health crises in the United States, significantly affecting the quality of life for millions. Traditional treatments often fall short in providing relief, leading to...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

1 May 2024

Harnessing Ketamine for Complex Psychiatric Cases: A Dual Diagnosis Approach

In the rapidly evolving landscape of psychiatric care, innovative treatments like ketamine assisted psychotherapy (KAP) hold promise for addressing complex, comorbid conditions that traditional therapies often struggle to manage....

By Madison Roberts

Breaking News

30 Apr 2024

MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials

MindBio Therapeutics Corp, a clinical stage biopharma company developing innovative psychiatric treatments using microdoses of psychedelic medicines to revolutionize mental health treatments, is delighted to announce the regulatory approval of...

By Madison Roberts

Finance

29 Apr 2024

Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology

Enveric Biosciences has signed two non-binding term sheets to out-license novel cannabinoid-COX-2 conjugate compounds for joint disease treatment, with potential financial gains from milestone payments and royalties totaling up to...

By Madison Roberts

Science

26 Apr 2024

The Tiny Dose That Gave A Big Sleep

A new study published in Nature Translational Psychiatry reveals that microdosing the psychedelic drug LSD causes people to sleep longer the next night. Could better sleep unlock some of microdosing's...

By Madison Roberts

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.